Compare VGZ & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VGZ | RZLT |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.7M | 321.6M |
| IPO Year | 1996 | 2011 |
| Metric | VGZ | RZLT |
|---|---|---|
| Price | $2.18 | $3.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.75 | ★ $9.67 |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $1.07 |
| 52 Week High | $3.13 | $11.46 |
| Indicator | VGZ | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 55.35 |
| Support Level | $2.02 | $2.91 |
| Resistance Level | $2.43 | $4.09 |
| Average True Range (ATR) | 0.14 | 0.33 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 28.92 | 46.63 |
Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.